PMID- 34267029
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 48
IP  - 7
DP  - 2021 Jul
TI  - Use of Ibrutinib in 10 Patients with Treatment-Naive or Relapsed/Refractory 
      Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical 
      Practice -A Report from a Single Medical Institution.
PG  - 921-926
AB  - In Japan, ibrutinib has been approved as both a front-line and later-line 
      treatment for chronic leukemia/small lymphocytic lymphoma(CLL/SLL). However, 
      little is known about the actual outcomes and adverse events(AEs)associated with 
      the use of ibrutinib in Japanese patients. OBJECTIVE: The outcomes and AEs of 
      patients treated with ibrutinib in a real-world setting were investigated. 
      METHODS: A retrospective cohort study of all patients with CLL/SLL who were 
      treated with ibrutinib at a single institution was conducted. RESULT: In total, 
      10 patients, including 5 treatment-naive patients(50%), were enrolled. The median 
      follow-up period was 9.8 months(range, 0.2-21.6 months), and the estimated 
      overall response rate (ORR: complete remission plus partial remission)was 60%. 
      The median overall survival and progression-free survival outcomes were not 
      reached. During the follow-up period, 4 patients(40%)had at least one AE and 1 
      patient(10%)had at least one grade>/=3 AE. Ibrutinib was discontinued in 4 
      patients(40%)because of AEs in 2 patients(20%), the progression of CLL in 1 
      patient(10%), and financial reasons in 1 patient(10%). Richter's transformation 
      did not occur in any of the cases. CONCLUSION: The ORR was lower(60%)than that 
      observed in clinical trials. The frequency and severity of AEs were both 
      relatively low, although the discontinuation rate was high(40%). Patient 
      education and medication adherence were considered important.
FAU - Sekiguchi, Yasunobu
AU  - Sekiguchi Y
AD  - Dept. of Hematology, Juntendo University Urayasu Hospital.
FAU - Iizuka, Hiroko
AU  - Iizuka H
FAU - Takizawa, Haruko
AU  - Takizawa H
FAU - Mitsumori, Toru
AU  - Mitsumori T
FAU - Tomita, Shigeki
AU  - Tomita S
FAU - Izumi, Hiroshi
AU  - Izumi H
FAU - Okubo, Mitsuo
AU  - Okubo M
FAU - Miyake, Kazunori
AU  - Miyake K
FAU - Osawa, Toshiya
AU  - Osawa T
FAU - Sawada, Tomohiro
AU  - Sawada T
FAU - Yoshikawa, Seiichirou
AU  - Yoshikawa S
FAU - Noguchi, Masaaki
AU  - Noguchi M
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Piperidines)
RN  - 0 (Pyrazoles)
RN  - 1X70OSD4VX (ibrutinib)
RN  - JAC85A2161 (Adenine)
SB  - IM
MH  - Adenine/analogs & derivatives
MH  - Humans
MH  - Japan
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
MH  - Piperidines
MH  - Pyrazoles/adverse effects
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2021/07/17 06:00
MHDA- 2021/07/20 06:00
CRDT- 2021/07/16 05:53
PHST- 2021/07/16 05:53 [entrez]
PHST- 2021/07/17 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2021 Jul;48(7):921-926.